Company Schedules Conference Call Wednesday, November 28th at 11:00AM ET to Update Investors on MuGard Commercial Activities

Dallas, TX and New York, NY, November 14, 2012 – ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program.

 

The investor conference call is scheduled to be held on Wednesday, November 28, 2012 at 11:00 am ET.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.

 

A replay of the call will be available starting on November 28, 2012 at 1:00 pm ET, through December 11, 2012 until 11:59 pm ET.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and conference ID number 377785.

 

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, and ProLindac™, a second generation DACH platinum drug. The Company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.